These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24803183)

  • 1. Effects of functional genetic polymorphisms in the CYP19A1 gene on prostate cancer risk and survival.
    Kanda S; Tsuchiya N; Narita S; Inoue T; Huang M; Chiba S; Akihama S; Saito M; Numakura K; Tsuruta H; Satoh S; Saito S; Ohyama C; Arai Y; Ogawa O; Habuchi T
    Int J Cancer; 2015 Jan; 136(1):74-82. PubMed ID: 24803183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.
    Huang CN; Huang SP; Pao JB; Hour TC; Chang TY; Lan YH; Lu TL; Lee HZ; Juang SH; Wu PP; Huang CY; Hsieh CJ; Bao BY
    J Intern Med; 2012 May; 271(5):499-509. PubMed ID: 21880074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer.
    Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X
    Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP19 (aromatase) haplotypes and endometrial cancer risk.
    Paynter RA; Hankinson SE; Colditz GA; Kraft P; Hunter DJ; De Vivo I
    Int J Cancer; 2005 Aug; 116(2):267-74. PubMed ID: 15800924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    Tang L; Platek ME; Yao S; Till C; Goodman PJ; Tangen CM; Wu Y; Platz EA; Neuhouser ML; Stanczyk FZ; Reichardt JKV; Santella RM; Hsing A; Figg WD; Lippman SM; Thompson IM; Ambrosone CB
    Carcinogenesis; 2018 Feb; 39(2):125-133. PubMed ID: 29228205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
    Park IH; Lee YS; Lee KS; Kim SY; Hong SH; Jeong J; Lee H; Ro J; Nam BH
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1263-71. PubMed ID: 21442439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors.
    Mononen N; Seppälä EH; Duggal P; Autio V; Ikonen T; Ellonen P; Saharinen J; Saarela J; Vihinen M; Tammela TL; Kallioniemi O; Bailey-Wilson JE; Schleutker J
    Cancer Res; 2006 Jan; 66(2):743-7. PubMed ID: 16424004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of CYP19A1 single-nucleotide polymorphism with digit ratio (2D:4D) in a sample of men and women from Ningxia (China).
    Zhanbing M; Jie D; Chunyue B; Hong L; Liang P; Zhenghao H
    Early Hum Dev; 2019 May; 132():58-65. PubMed ID: 30986648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men.
    Jiang J; Tang NL; Ohlsson C; Eriksson AL; Vandenput L; Chan FW; Ching JK; Kwok A; Orwoll E; Kwok TC; Woo J; Leung PC
    Clin Chim Acta; 2010 Jan; 411(1-2):53-8. PubMed ID: 19818337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men.
    Shiota M; Fujimoto N; Tsukahara S; Ushijima M; Takeuchi A; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Eto M
    Cancer Chemother Pharmacol; 2019 May; 83(5):933-938. PubMed ID: 30868236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.
    Haiman CA; Dossus L; Setiawan VW; Stram DO; Dunning AM; Thomas G; Thun MJ; Albanes D; Altshuler D; Ardanaz E; Boeing H; Buring J; Burtt N; Calle EE; Chanock S; Clavel-Chapelon F; Colditz GA; Cox DG; Feigelson HS; Hankinson SE; Hayes RB; Henderson BE; Hirschhorn JN; Hoover R; Hunter DJ; Kaaks R; Kolonel LN; Le Marchand L; Lenner P; Lund E; Panico S; Peeters PH; Pike MC; Riboli E; Tjonneland A; Travis R; Trichopoulos D; Wacholder S; Ziegler RG
    Cancer Res; 2007 Mar; 67(5):1893-7. PubMed ID: 17325027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol-related breast cancer in postmenopausal women - effect of CYP19A1, PPARG and PPARGC1A polymorphisms on female sex-hormone levels and interaction with alcohol consumption and NSAID usage in a nested case-control study and a randomised controlled trial.
    Kopp TI; Jensen DM; Ravn-Haren G; Cohen A; Sommer HM; Dragsted LO; Tjonneland A; Hougaard DM; Vogel U
    BMC Cancer; 2016 Apr; 16():283. PubMed ID: 27102200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.
    Long JR; Kataoka N; Shu XO; Wen W; Gao YT; Cai Q; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2115-22. PubMed ID: 17119036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
    Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
    Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.
    Umamaheswaran G; Dkhar SA; Kalaivani S; Anjana R; Revathy M; Jaharamma M; Shree KM; Kadambari D; Adithan C
    Med Oncol; 2013; 30(3):665. PubMed ID: 23893151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP19A1 gene polymorphisms and risk of lung cancer.
    Zhang J; Yin Y; Niu XM; Liu Y; Garfield D; Chen SF; Wang R; Wang L; Chen HQ
    J Int Med Res; 2013 Jun; 41(3):735-42. PubMed ID: 23669293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.